ORIC Pharmaceuticals Inc
ORICHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 7:17 AM ET
8.55+0.05 (0.59%)
2026-11-13 13:38 CET
Market cap
$886.23M
Revenue, TTM
0.00 USD m
Net income, TTM
-140.35 USD m
Free cash flow, TTM
-114.99 USD m
EPS diluted, TTM
-1.35
Price
ORIC against its 20, 50 and 200-day averagesPatternshover a marker to name it
41.8% under the 52-week high of 14.68 on 19 Aug 2026. 52-week low 7.23 on 2 Apr 2026. Last 15 sessions, 59.9% high to low
Volume 0.01× normal · the line is the 50-bar volume average
Setup. RS line 40
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 4 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Minervini 1 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
ORIC52-week range, 18% of the way up
7.2314.68
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
| Index | RUT |
|---|---|
| Employees | 104 |
| IPO | Apr 24, 2020 |
| Beta | 1.22 |
| ATR, 14d | 0.84 |
| Rel volume | 0.01 |
| Short float | 15.73% |
| Insider own | 34.19% |
| Inst own | 86.70% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $886.23M |
| Enterprise Value | 624.80M |
| Income | -140.35M |
| Sales | 0.00M |
| Book / share | 3.68 |
| Cash / share | 2.55 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 104 |
| IPO | Apr 24, 2020 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 2.32 |
| Price / cash | 3.35 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 13.19 |
| Current Ratio | 13.19 |
| Debt / equity | 0.01 |
| Long-term debt / equity | 0.00 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.35 |
|---|---|
| Earnings next year | -1.71 |
| Earnings next quarter | -0.39 |
| Earnings this year | -3.22% |
| Earnings next year | -12.44% |
| Earnings growth, 5 years | -9.44% |
| Past earnings growth | 13.10% 15.18% |
| Past sales growth | - - |
| Earnings vs last year | 28.64% |
| Sales vs last year | - |
| Earnings vs last quarter | 17.45% |
| Sales vs last quarter | - |
| Earnings | Aug 03 AMC |
| Surprise | -5.76% - |
Ownership
| Insiders own | 34.19% |
|---|---|
| Insider trades | -0.35% |
| Institutions own | 86.70% |
| Institution trades | 4.77% |
| Return on assets | -37.35% |
| Return on equity | -39.80% |
| Return on capital | -36.81% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -15.40% |
| 50-day average | -26.10% |
| 200-day average | -22.26% |
Technical
| Shares out | 103.64M |
|---|---|
| Shares floating | 68.21M |
| Short / float | 15.73% |
| Short ratio | 6.91 |
| Short interest | 10.73M |
| 52-week high | 14.68 -41.8% |
| 52-week low | 7.23 +18.3% |
| Volatility | 5.71% 9.86% |
| Average range | 0.84 |
| Strength index | 35.27 |
| Market sensitivity | 1.22 |
| Relative volume | 0.01 |
| Avg Volume | 1.55M |
| Volume | 552 |
Performance
| Perf Week | -3.06% |
|---|---|
| Perf Month | -33.05% |
| Perf Quarter | -36.10% |
| Perf Half Y | 4.91% |
| Perf YTD | 4.52% |
| Perf Year | -29.86% |
| Perf 3Y | 39.48% |
| Perf 5Y | -51.48% |
| Perf 10Y | - |
| Recommendation | 1.14 |
| Target Price | 22.75 |
| Prev Close | 8.50 |
| Price | 8.55 |
| Change % | 0.59% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Oct 05, 2026 | Initiated | Leerink Partners | Outperform | $26 | +204.1% |
| Sep 23, 2026 | Initiated | BTIG Research | Buy | $26 | +204.1% |
| Jun 12, 2026 | Resumed | Stifel | Buy | $14 | +63.7% |
| May 15, 2026 | Upgrade | Goldman | Neutral → Buy | $15 | +75.4% |
| Jan 07, 2026 | Initiated | Piper Sandler | Overweight | $22 | +157.3% |
| Nov 20, 2025 | Initiated | Evercore ISI | Outperform | $25 | +192.4% |
| Nov 18, 2025 | Initiated | Wolfe Research | Peer Perform | ||
| Sep 04, 2025 | Resumed | Guggenheim | Buy | $18 | +110.5% |
| Jul 08, 2025 | Initiated | Ladenburg Thalmann | Buy | $15 | +75.4% |
| Oct 31, 2024 | Initiated | Wells Fargo | Overweight | $20 | +133.9% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| CGEM | Cullinan Therapeutics Inc | 661.54M |
| JANX | Janux Therapeutics Inc | 704.74M |
| ARVN | Arvinas Inc | 438.44M |
| BDTX | Black Diamond Therapeutics Inc | 89.17M |
| NUVB | Nuvation Bio Inc | 1.44B |
| IDYA | Ideaya Biosciences Inc | 3.04B |
| TYRA | Tyra Biosciences Inc | 1.34B |
| ERAS | Erasca Inc | 5.52B |
| RLAY | Relay Therapeutics Inc | 4.00B |
| TNGX | Tango Therapeutics Inc | 4.21B |
Insider trading
latest 14 of 38| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer | Oct 20 '26 | Option Exercise | 4.36 | 14,000 | 61,040 | 83,828 | Oct 21 05:17 PM |
| Piscitelli Dominic | Chief Financial Officer | Oct 20 '26 | Sale | 13.53 | 14,000 | 189,391 | 69,828 | Oct 21 05:17 PM |
| Heyman Richard A. | Director | Oct 01 '26 | Option Exercise | 1.60 | 3,500 | 5,600 | 41,800 | Oct 02 05:50 PM |
| Heyman Richard A. | Director | Oct 01 '26 | Sale | 12.91 | 3,500 | 45,199 | 38,300 | Oct 02 05:50 PM |
| Heyman Richard A. | Director | Oct 01 '26 | Sale | 12.91 | 3,200 | 41,325 | 203,472 | Oct 02 05:50 PM |
| Richard A, Heyman | Director | Oct 01 '26 | Proposed Sale | 13.47 | 8,100 | 109,107 | Oct 01 04:23 PM | |
| Richard A, Heyman | Director | Oct 01 '26 | Proposed Sale | 13.47 | 7,600 | 102,372 | Oct 01 04:23 PM | |
| Piscitelli Dominic | Chief Financial Officer | Sep 28 '26 | Option Exercise | 4.36 | 13,400 | 58,424 | 83,228 | Sep 29 07:16 PM |
| Piscitelli Dominic | Chief Financial Officer | Sep 28 '26 | Sale | 13.53 | 13,400 | 181,258 | 69,828 | Sep 29 07:16 PM |
| Piscitelli Dominic | Chief Financial Officer | Sep 24 '26 | Option Exercise | 4.36 | 600 | 2,616 | 70,428 | Sep 25 07:59 PM |
| Piscitelli Dominic | Chief Financial Officer | Sep 24 '26 | Sale | 13.50 | 600 | 8,102 | 69,828 | Sep 25 07:59 PM |
| Piscitelli Dominic | Chief Financial Officer | Aug 26 '26 | Option Exercise | 4.89 | 77,000 | 376,720 | 146,828 | Aug 28 04:11 PM |
| Piscitelli Dominic | Chief Financial Officer | Aug 26 '26 | Sale | 13.69 | 77,000 | 1,053,814 | 69,828 | Aug 28 04:11 PM |
| Dominic Piscitelli | Officer | Aug 26 '26 | Proposed Sale | 13.50 | 229,500 | 3,098,250 | Aug 26 04:09 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.44B |
| DFAC | U.S. Core Equity 2 Portfolio-ETF Class Shares | AUM: 49.67B |
News
latest 14 of 200- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.73%
- ORIC Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 (GlobeNewswire)
- ORIC Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial (GlobeNewswire)
- ORIC Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 (GlobeNewswire)
- ORIC Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development (GlobeNewswire)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- ORIC Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates (GlobeNewswire) +27.08%
- ORIC Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire)
- ORIC Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA (Darolutamide), Supported by Clinical Collaboration with Bayer (GlobeNewswire) +5.59%
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.89% -6.27%
Quarterly earnings
2026Q2 EPS -0.380 missed -0.359, from -0.470 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-08-03 16:30 | -0.380 | -0.359 | -0.380 | 0.00 | 0.00 | EPS +5.8% · sales - | vs 2025Q2, year-ago quarter · EPS -19.1% · sales - | 15 EPS · 8 sales | Open +0.38% vs SPY +0.39%. Close +27.08% vs SPY +1.80% |
| 2026Q1ended 2026-03-31 | 2026-05-04 16:30 | -0.340 | -0.321 | -0.339 | 0.00 | 0.00 | EPS +6.0% · sales - | vs 2025Q1, year-ago quarter · EPS -19.0% · sales - | 16 EPS · 8 sales | Open -2.28% vs SPY +0.52%. Close -0.62% vs SPY +0.80% |
| 2025Q4ended 2025-12-31 | 2026-02-24 08:30 | -0.300 | -0.340 | -0.297 | 0.00 | 0.00 | EPS -11.7% · sales - | vs 2024Q4, year-ago quarter · EPS -41.2% · sales - | 15 EPS · 9 sales | Open +3.16% vs SPY -0.07%. Close +14.60% vs SPY +0.73% |
| 2025Q3ended 2025-09-30 | 2025-11-13 16:30 | -0.330 | -0.405 | -0.329 | 0.00 | 0.00 | EPS -18.6% · sales - | vs 2024Q3, year-ago quarter · EPS -32.7% · sales - | 12 EPS · 5 sales | Open +2.05% vs SPY -0.99%. Close +0.49% vs SPY -0.02% |
| 2025Q2ended 2025-06-30 | 2025-08-12 16:30 | -0.470 | -0.443 | -0.465 | 0.00 | 0.00 | EPS +6.1% · sales - | vs 2024Q2, year-ago quarter · EPS +4.4% · sales - | 10 EPS · 4 sales | Open +0.42% vs SPY +0.35%. Close +3.26% vs SPY +0.34% |
| 2025Q1ended 2025-03-31 | 2025-05-05 16:30 | -0.420 | -0.511 | -0.423 | 0.00 | 0.00 | EPS -17.8% · sales - | vs 2024Q1, year-ago quarter · EPS +13.5% · sales - | 9 EPS · 5 sales | Open +2.28% vs SPY -0.99%. Close -11.58% vs SPY -0.84% |
| 2024Q4ended 2024-12-31 | 2025-02-18 16:30 | -0.510 | -0.500 | -0.514 | 0.00 | 0.00 | EPS +1.9% · sales - | vs 2023Q4, year-ago quarter · EPS +4.1% · sales - | 11 EPS · 8 sales | Open +9.17% vs SPY -0.23%. Close +1.15% vs SPY +0.24% |
| 2024Q3ended 2024-09-30 | 2024-11-12 16:30 | -0.490 | -0.478 | -0.490 | 0.00 | 0.00 | EPS +2.5% · sales - | vs 2023Q3, year-ago quarter · EPS +11.4% · sales - | 12 EPS · 7 sales | Open -0.29% vs SPY +0.08%. Close +0.10% vs SPY +0.05% |
| 2024Q2ended 2024-06-30 | 2024-08-12 16:30 | -0.450 | -0.412 | -0.454 | 0.00 | 0.00 | EPS +9.1% · sales - | vs 2023Q2, year-ago quarter · EPS -10.0% · sales - | 9 EPS · 4 sales | Open -0.24% vs SPY +0.61%. Close +6.76% vs SPY +1.64% |
| 2024Q1ended 2024-03-31 | 2024-05-06 16:30 | -0.370 | -0.429 | -0.371 | 0.00 | 0.00 | EPS -13.8% · sales - | vs 2023Q1, year-ago quarter · EPS -30.2% · sales - | 9 EPS · 4 sales | Open +0.75% vs SPY +0.19%. Close +2.56% vs SPY +0.11% |
| 2023Q4ended 2023-12-31 | 2024-03-11 16:30 | -0.490 | -0.478 | -0.493 | 0.00 | 0.00 | EPS +2.6% · sales - | vs 2022Q4, year-ago quarter · EPS -5.8% · sales - | 9 EPS · 5 sales | Open -2.40% vs SPY +0.42%. Close -4.47% vs SPY +1.08% |
| 2023Q3ended 2023-09-30 | 2023-11-06 16:30 | -0.440 | -0.462 | -0.444 | 0.00 | 0.00 | EPS -4.8% · sales - | vs 2022Q3, year-ago quarter · EPS -30.2% · sales - | 8 EPS · 4 sales | Open -1.45% vs SPY 0.00%. Close -0.72% vs SPY +0.28% |
| 2023Q2ended 2023-06-30 | 2023-08-10 16:30 | -0.500 | -0.569 | -0.503 | 0.00 | 0.00 | EPS -12.1% · sales - | vs 2022Q2, year-ago quarter · EPS -2.0% · sales - | 7 EPS · 1 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-08 16:30 | -0.530 | -0.540 | -0.531 | 0.00 | 0.00 | EPS -1.9% · sales - | vs 2022Q1, year-ago quarter · EPS -10.2% · sales - | 6 EPS · 2 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-16 16:30 | -0.520 | -0.548 | -0.519 | 0.00 | 0.00 | EPS -5.1% · sales - | vs 2021Q4, year-ago quarter · EPS -10.3% · sales - | 6 EPS · 2 sales | - |
| 2022Q3ended 2022-09-30 | 2022-11-07 16:30 | -0.630 | -0.553 | -0.627 | 0.00 | 0.00 | EPS +13.9% · sales - | vs 2021Q3, year-ago quarter · EPS +34.0% · sales - | 7 EPS · 2 sales | - |
Annual earnings
2025FY EPS -1.470 beat -1.517, from -1.830 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -1.427 | - | - | 207.55 | - |
| 2029FYestimate | - | -2.240 | - | - | 32.77 | - |
| 2028FYestimate | - | -1.927 | - | - | 0.00 | - |
| 2027FYestimate | - | -1.706 | - | - | 0.00 | - |
| 2026FYestimate | - | -1.517 | - | - | 0.00 | - |
| 2025FY | -1.470 | -1.517 | -1.470 | 0.00 | 0.00 | - |
| 2024FY | -1.830 | -1.852 | -1.834 | 0.00 | 0.00 | - |
| 2023FY | -1.960 | -1.956 | -1.957 | 0.00 | 0.00 | - |
| 2022FY | -2.250 | -2.239 | -2.247 | 0.00 | 0.00 | - |
| 2021FY | -2.070 | -2.061 | -2.074 | 0.00 | 0.00 | - |
| 2020FY | -3.360 | -2.948 | -3.359 | 0.00 | 0.00 | - |
| 2019FY | -2.470 | - | -0.899 | 0.00 | - | - |
Quarterly results
2026Q2 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -1.52 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-12 | -1.52 | +0.8% |
| 2026Q3 | E | per share | 2026-11-12 | -0.39 | +1.5% |
| 2026FY | R | per share | 2026-11-12 | -1.52 | +0.8% |
| 2026Q3 | R | per share | 2026-11-12 | -0.40 | +1.4% |
| 2026FY | S | per share | 2026-11-12 | 0.00 | - |
| 2026Q3 | S | per share | 2026-11-12 | 0.00 | - |
| 2026Q2 | E | per share | 2026-07-27 | -0.36 | -0.4% |
| 2026Q2 | S | per share | 2026-07-21 | 0.00 | - |
| 2026Q2 | R | per share | 2026-07-19 | -0.34 | 0.0% |
| 2026Q1 | E | per share | 2026-04-17 | -0.32 | 0.0% |
| 2026Q1 | R | per share | 2026-03-30 | -0.31 | -0.6% |
| 2026Q1 | S | per share | 2026-03-15 | 0.00 | - |
| 2025FY | E | per share | 2026-02-23 | -1.54 | -3.9% |
| 2025Q4 | E | per share | 2026-02-23 | -0.36 | -0.8% |
| 2025FY | S | per share | 2026-02-20 | 0.00 | - |
| 2025Q4 | S | per share | 2026-02-20 | 0.00 | - |
| 2025FY | R | per share | 2026-02-18 | -1.56 | 0.0% |
| 2025Q4 | R | per share | 2026-02-18 | -0.34 | 0.0% |
| 2025Q3 | E | per share | 2025-10-28 | -0.41 | 0.0% |
| 2025Q3 | R | per share | 2025-10-28 | -0.41 | 0.0% |
| 2025Q3 | S | per share | 2025-09-08 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-11 | -0.44 | 0.0% |
| 2025Q2 | R | per share | 2025-08-11 | -0.42 | 0.0% |
| 2025Q2 | S | per share | 2025-06-05 | 0.00 | - |
| 2025Q1 | E | per share | 2025-05-05 | -0.51 | 0.0% |
| 2025Q1 | S | per share | 2025-04-09 | 0.00 | - |
| 2025Q1 | R | per share | 2025-03-07 | -0.52 | +0.3% |
| 2024FY | E | per share | 2025-02-12 | -1.85 | -0.2% |
| 2024Q4 | E | per share | 2025-02-12 | -0.50 | -0.7% |
| 2024FY | R | per share | 2025-02-05 | -1.83 | +0.0% |
| 2024Q4 | R | per share | 2025-02-05 | -0.51 | 0.0% |
| 2024FY | S | per share | 2025-02-05 | 0.00 | - |
| 2024Q4 | S | per share | 2025-02-05 | 0.00 | - |
| 2024Q3 | E | per share | 2024-11-09 | -0.48 | 0.0% |
| 2024Q3 | S | per share | 2024-10-30 | 0.00 | - |
| 2024Q3 | R | per share | 2024-10-29 | -0.48 | -0.3% |
| 2024Q2 | E | per share | 2024-07-21 | -0.41 | 0.0% |
| 2024Q2 | R | per share | 2024-07-21 | -0.41 | 0.0% |
| 2024Q2 | S | per share | 2024-05-07 | 0.00 | - |
| 2024Q1 | E | per share | 2024-04-17 | -0.43 | +2.9% |
| 2024Q1 | S | per share | 2024-04-17 | 0.00 | - |
| 2024Q1 | R | per share | 2024-03-26 | -0.42 | +1.1% |
| 2023FY | E | per share | 2024-03-06 | -1.96 | 0.0% |
| 2023FY | R | per share | 2024-03-06 | -1.96 | -0.1% |
| 2023FY | S | per share | 2024-03-05 | 0.00 | - |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.737 | -0.714 | -0.899 | -3.359 | -2.074 | -2.247 | -1.957 | -1.834 | -1.475 | -1.3499 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 30 | 30 | 30 | 37 | 39 | 45 | 55 | 71 | 99 | - | 104 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.454 | -0.49 | -0.514 | -0.423 | -0.465 | -0.329 | -0.297 | -0.339 | -0.384 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 68 | 71 | 71 | 71 | 86 | 97 | 99 | 103 | 104 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 1.14 | 1.22+9.9% | 1.11+7.8% | 1.03+6.2% | 0.97+7.8% | 0.90-7.2% | 0.97-3.0% | 1.00+11.1% | 0.90 |
| Gross Profit | -1.14 | -1.22 | -1.11 | -1.03 | -0.97 | -0.90 | -0.97 | -1.00 | -0.90 |
| Selling, General and Administrative Excl. Other | 155.00 | 141.780.0% | 141.79+29.2% | 109.75+27.9% | 85.80+10.0% | 77.97+61.2% | 48.37+75.4% | 27.57+28.4% | 21.47 |
| Research and Development | 122.36 | 109.82-3.7% | 114.07+33.9% | 85.17+38.1% | 61.68+8.5% | 56.86+58.3% | 35.92+57.3% | 22.84+20.0% | 19.03 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -156.14 | -143.00 | -142.90 | -110.78 | -86.77 | -78.87 | -49.34 | -28.57 | -22.37 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 5.00 | 0.00-100.0% | 24.84 | - | - |
| Net Income Before Taxes | -140.35 | -129.47 | -127.85 | -100.70 | -89.12 | -78.72 | -73.70 | -26.88 | -21.36 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -140.35 | -129.47 | -127.85 | -100.70 | -89.12 | -78.72 | -73.70 | -26.88 | -21.36 |
| Net Income From Continuing Operations | -140.35 | -129.47 | -127.85 | -100.70 | -89.12 | -78.72 | -73.70 | -26.88 | -21.36 |
| Net Income | -140.35 | -129.47 | -127.85 | -100.70 | -89.12 | -78.72 | -73.70 | -26.88 | -21.36 |
| EPS (Recurring) per share | -1.30 | -1.47 | -1.83 | -1.96 | -2.16 | -2.07 | -2.57 | -0.90 | -0.71 |
| EPS (Basic, Before Extraordinaries) per share | -1.35 | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 | -3.36 | -0.90 | -0.71 |
| EPS (Diluted) per share | -1.35 | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 | -3.36 | -0.90 | -0.71 |
| EBITDA | -155.00 | -141.78 | -141.79 | -109.75 | -85.80 | -77.97 | -48.37 | -27.57 | -21.47 |
| Non-Operating Income (Expense) | 15.79 | 13.54-10.0% | 15.05+49.3% | 10.08+280.4% | 2.65+1556.3% | 0.16-66.7% | 0.48-71.6% | 1.69+67.3% | 1.01 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 25.90 | 25.04+23.9% | 20.21+32.7% | 15.23+5.3% | 14.46+12.5% | 12.85+143.4% | 5.28+384.4% | 1.09+131.9% | 0.47 |
| Shares Outstanding million shares | 103.64 | 98.53+38.7% | 71.02+29.4% | 54.87+21.7% | 45.09+14.4% | 39.43+7.5% | 36.67+22.6% | 29.900.0% | 29.90 |
| Market Capitalization | 881.05 | 881.05+54.7% | 569.48+13.5% | 501.87+115.3% | 233.11-59.7% | 578.91-52.3% | 1,214.46-7.7% | 1,315.64 | - |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.26-16.1% | 0.27-10.0% | 0.32+6.7% | 0.29+7.4% | 0.31+14.8% | 0.30+15.4% | 0.30+15.4% | 0.27+3.8% |
| Gross Profit | -0.26 | -0.27 | -0.32 | -0.29 | -0.31 | -0.30 | -0.30 | -0.27 |
| Selling, General and Administrative Excl. Other | 45.03+16.2% | 39.35+21.4% | 34.23-12.8% | 36.38-4.4% | 38.75+8.4% | 32.42+12.8% | 39.27+26.0% | 38.05+33.8% |
| Research and Development | 36.30+18.8% | 31.44+27.6% | 25.86-19.1% | 28.77-7.8% | 30.55+5.6% | 24.64+12.2% | 31.97+30.6% | 31.20+39.3% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -45.30 | -39.62 | -34.55 | -36.67 | -39.06 | -32.72 | -39.57 | -38.32 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -41.49 | -35.77 | -30.50 | -32.59 | -36.35 | -30.02 | -36.31 | -34.57 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -41.49 | -35.77 | -30.50 | -32.59 | -36.35 | -30.02 | -36.31 | -34.57 |
| Net Income From Continuing Operations | -41.49 | -35.77 | -30.50 | -32.59 | -36.35 | -30.02 | -36.31 | -34.57 |
| Net Income | -41.49 | -35.77 | -30.50 | -32.59 | -36.35 | -30.02 | -36.31 | -34.57 |
| EPS (Recurring) per share | -0.38 | -0.34 | -0.30 | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 |
| EPS (Basic, Before Extraordinaries) per share | -0.38 | -0.34 | -0.30 | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 |
| EPS (Diluted) per share | -0.38 | -0.34 | -0.30 | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 |
| EBITDA | -45.03 | -39.35 | -34.23 | -36.38 | -38.75 | -32.42 | -39.27 | -38.05 |
| Non-Operating Income (Expense) | 3.80+40.2% | 3.85+42.6% | 4.05+24.2% | 4.08+8.8% | 2.71-33.1% | 2.70-32.2% | 3.26+5.2% | 3.75+17.2% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 7.09+7.9% | 6.90+5.3% | 6.28+20.8% | 5.63+11.3% | 6.57+31.4% | 6.55+32.1% | 5.20+32.7% | 5.06+31.1% |
| Shares Outstanding million shares | 103.64+20.2% | 103.49+45.6% | 98.53+38.7% | 97.28+37.9% | 86.19+27.4% | 71.08+5.4% | 71.02+29.4% | 70.56+29.4% |
| Market Capitalization | 881.05+1.9% | 1,271.54+220.8% | 796.64+39.9% | 1,165.48+61.2% | 865.03+81.5% | 396.33-57.2% | 569.48+13.5% | 723.06+119.2% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 281.49+10.0% | 255.96+22.9% | 208.19+0.9% | 206.27-13.0% | 236.98-19.3% | 293.60+229.3% | 89.16+109.1% | 42.64+65.1% | 25.82 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 6.98+11.0% | 6.29+42.6% | 4.41+5.5% | 4.18+18.1% | 3.54+14.2% | 3.10+269.0% | 0.84-22.9% | 1.09+38.0% | 0.79 |
| Total Current Assets | 288.47+10.0% | 262.25+23.4% | 212.60+1.0% | 210.46-12.5% | 240.52-18.9% | 296.70+229.7% | 90.00+105.9% | 43.72+64.3% | 26.61 |
| Net Property, Plant & Equipment | 9.07-19.7% | 11.30-5.9% | 12.01-15.7% | 14.25+0.3% | 14.21+617.7% | 1.98-11.6% | 2.24-10.8% | 2.51-13.4% | 2.90 |
| Total Investments and Advances | 111.25+22604.1% | 0.49-98.2% | 27.34+21.9% | 22.42-48.9% | 43.85 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | 2.11-18.5% | 2.59-3.4% | 2.68-15.7% | 3.18-6.7% | 3.41 | - | - | - | - |
| Other Assets | 0.100.0% | 0.10+66.7% | 0.06+20.0% | 0.050.0% | 0.05-84.4% | 0.32-82.7% | 1.85+270.0% | 0.50-2.0% | 0.51 |
| Total Assets | 411.00+48.5% | 276.73+8.7% | 254.69+1.7% | 250.36-17.1% | 302.06+1.0% | 299.00+217.8% | 94.09+101.3% | 46.73+55.7% | 30.02 |
| Short Term Debt Incl. Current Port. of LT Debt | 3.33+4.7% | 3.18+15.6% | 2.75+3.4% | 2.66+37.8% | 1.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 3.82+146.5% | 1.55+64.9% | 0.94-28.8% | 1.32-30.2% | 1.89+148.7% | 0.76+406.7% | 0.15-66.7% | 0.45-52.1% | 0.94 |
| Other Current Liabilities | 13.26-34.1% | 20.11+20.0% | 16.76+46.9% | 11.41+0.6% | 11.34+37.6% | 8.24+58.5% | 5.20+141.9% | 2.15+28.7% | 1.67 |
| Total Current Liabilities | 20.42-17.8% | 24.85+21.5% | 20.46+32.9% | 15.39+1.6% | 15.15+68.3% | 9.00+68.2% | 5.35+105.8% | 2.60-0.4% | 2.61 |
| Long Term Debt | 4.11-33.4% | 6.17-17.3% | 7.46-21.0% | 9.44-10.3% | 10.52 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 2.11-18.5% | 2.59-3.4% | 2.68-15.7% | 3.18-6.7% | 3.41 | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.22-71.4% | 0.77-40.8% | 1.30-23.1% | 1.69 |
| Total Liabilities | 26.64-20.7% | 33.61+9.8% | 30.60+9.2% | 28.01-3.7% | 29.08+215.4% | 9.22+50.7% | 6.12+57.3% | 3.89-9.5% | 4.30 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 178.06+66.0% | 107.27+54.7% | 69.34 |
| Common Equity | 384.36+58.1% | 243.12+8.5% | 224.09+0.8% | 222.35-18.5% | 272.98-5.8% | 289.78 | -90.08 | -64.43 | -43.61 |
| Total Shareholders Equity | 384.36+58.1% | 243.12+8.5% | 224.09+0.8% | 222.35-18.5% | 272.98-5.8% | 289.78+229.4% | 87.97+105.3% | 42.84+66.5% | 25.73 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 384.36+58.1% | 243.12+8.5% | 224.09+0.8% | 222.35-18.5% | 272.98-5.8% | 289.78+229.4% | 87.97+105.3% | 42.84+66.5% | 25.73 |
| Total Liabilities & Stockholders Equity | 411.00+48.5% | 276.73+8.7% | 254.69+1.7% | 250.36-17.1% | 302.06+1.0% | 299.00+217.8% | 94.09+101.3% | 46.73+55.7% | 30.02 |
| Book Value Per Share per share | 3.90+14.0% | 3.42-16.2% | 4.08-17.2% | 4.93-28.8% | 6.92-12.4% | 7.90 | -3.01 | -2.15 | -1.46 |
| Tangible Book Value Per Share per share | 3.90+14.0% | 3.42-16.2% | 4.08-17.2% | 4.93-28.8% | 6.92-12.4% | 7.90 | -3.01 | -2.15 | -1.46 |
| Full-Time Employees people | 104-9.6% | 115+15.0% | 100+16.3% | 86+10.3% | 78+27.9% | 61+7.0% | 57 | - | - |
| Price to Book Ratio ratio | 2.31 | 2.08 | 2.03 | 1.09 | 2.12 | 4.28 | 6.08 | - | - |
| Return on Assets % | -37.65 | -48.12 | -39.88 | -32.27 | -26.19 | -37.50 | -38.18 | -55.66 | - |
| Return on Equity % | -41.27 | -54.73 | -45.11 | -35.99 | -27.98 | -39.02 | -41.10 | -62.31 | - |
| Return on Invested Capital % | -33.33 | -51.28 | -43.49 | -38.45 | -27.77 | -25.43 | -30.56 | -49.87 | -85.63 |
| Quick Ratio ratio | 14.13 | 10.56 | 10.39 | 13.68 | 15.87 | 32.96 | 16.81 | 16.84 | 10.20 |
| Current Ratio ratio | 14.13 | 10.56 | 10.39 | 13.68 | 15.87 | 32.96 | 16.81 | 16.84 | 10.20 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -140.35 | -129.47 | -127.85 | -100.70 | -89.12 | -78.72 | -73.70 | -26.88 | -21.36 |
| Depreciation | 1.14 | 1.22+9.9% | 1.11+7.8% | 1.03+6.2% | 0.97+7.8% | 0.90-7.2% | 0.97-5.8% | 1.03+14.4% | 0.90 |
| Other Funds (Non Cash) | 22.79 | 20.34+70.4% | 11.94+34.9% | 8.85-32.2% | 13.06+5.7% | 12.35-51.4% | 25.42+2442.0% | 1.00+108.3% | 0.48 |
| Funds from Operations | -116.42 | -107.91 | -114.80 | -90.81 | -75.10 | -65.47 | -47.31 | -24.85 | -19.98 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 2.05 | -5.46-377.2% | 1.97-59.8% | 4.90 | -0.45-111.1% | 4.07+99.5% | 2.04+67.2% | 1.22 | -0.71 |
| Cash from Operating Activities | -114.37 | -113.37 | -112.83 | -85.92 | -75.54 | -61.39 | -45.27 | -23.63 | -20.68 |
| Capital Expenditures | -0.62 | -0.71 | -1.19 | -0.85 | -2.08 | -0.94 | -0.67 | -0.77 | -0.53 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -99.04 | -147.32-731.7% | 23.32 | -42.55 | -107.17-167.2% | 159.37 | -215.49 | 0.00 | 0.00 |
| Purchase of Investments | -336.54 | -399.82 | -251.92 | -239.24 | -238.12 | -69.63 | -225.49 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 237.50 | 252.50-8.3% | 275.25+39.9% | 196.69+50.2% | 130.95-42.8% | 229.00+2190.0% | 10.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.19 | 0.00-100.0% | 0.02 |
| Cash from Investing Activities | -99.66 | -148.03-768.6% | 22.14 | -43.40 | -109.25-169.0% | 158.44 | -215.96 | -0.77 | -0.51 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 175.65 | 247.66+95.4% | 126.72+47.5% | 85.89+235.2% | 25.62-49.8% | 50.99-79.6% | 250.51+253.2% | 70.92+86.6% | 38.01 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 175.65 | 247.66+95.4% | 126.72+47.5% | 85.89+235.2% | 25.62-49.8% | 50.99-79.6% | 250.51+253.2% | 70.92+86.6% | 38.01 |
| Proceedsfrom Stock Options | 307.24 | 245.68+94.9% | 126.08+46.9% | 85.83+235.9% | 25.55-48.9% | 50.00-80.0% | 250.07+252.6% | 70.92+86.6% | 38.01 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 175.65 | 247.66+95.4% | 126.72+47.5% | 85.89+235.2% | 25.62-49.8% | 50.99-79.6% | 250.51+253.2% | 70.92+86.6% | 38.01 |
| Net Change in Cash | -38.38 | -13.74-138.1% | 36.02 | -43.43 | -159.17-207.5% | 148.03 | -10.71-123.0% | 46.52+176.6% | 16.82 |
| Free Cash Flow | -114.99 | -114.08 | -114.02 | -86.76 | -77.62 | -62.33 | -45.94 | -24.40 | -21.21 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 264.76-6.3% | 281.93+38.4% | 281.49+10.0% | 287.14+5.4% | 282.51-1.4% | 203.72-35.7% | 255.96+22.9% | 272.37+19.8% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 8.93+3.7% | 8.30+7.7% | 6.98+11.0% | 8.45+19.7% | 8.61+5.1% | 7.71+5.6% | 6.29+42.6% | 7.06+42.9% |
| Total Current Assets | 273.69-6.0% | 290.23+37.3% | 288.47+10.0% | 295.59+5.8% | 291.12-1.2% | 211.43-34.8% | 262.25+23.4% | 279.43+20.3% |
| Net Property, Plant & Equipment | 2.24-18.8% | 2.15-28.8% | 9.07-19.7% | 2.56-17.2% | 2.76-4.2% | 3.02+7.9% | 11.30-5.9% | 3.09+1.0% |
| Total Investments and Advances | 123.29+169.7% | 138.27+573.5% | 111.25+22604.1% | 126.40+1105.0% | 45.71+102.1% | 20.53+35.2% | 0.49-98.2% | 10.49-64.3% |
| Deferred Tax Assets | - | - | 2.11-18.5% | - | - | - | 2.59-3.4% | - |
| Other Assets | 5.46-24.8% | 6.11-22.4% | 0.100.0% | 6.64-26.7% | 7.26-17.6% | 7.87-9.7% | 0.10+66.7% | 9.06-6.4% |
| Total Assets | 404.69+16.7% | 436.76+79.8% | 411.00+48.5% | 431.19+42.7% | 346.86+5.5% | 242.86-30.8% | 276.73+8.7% | 302.07+10.1% |
| Short Term Debt Incl. Current Port. of LT Debt | 3.33+1.8% | 3.30+2.8% | 3.33+4.7% | 3.30+5.8% | 3.27+18.1% | 3.21+15.9% | 3.18+15.6% | 3.12+14.3% |
| Accounts Payable | 3.87+23.6% | 2.90-43.8% | 3.82+146.5% | 2.90-31.8% | 3.13+35.5% | 5.16+72.6% | 1.55+64.9% | 4.25+13.6% |
| Other Current Liabilities | 13.56+16.4% | 11.58+25.3% | 13.26-34.1% | 13.98+0.7% | 11.65-19.4% | 9.24-2.2% | 20.11+20.0% | 13.88+11.2% |
| Total Current Liabilities | 20.76+15.0% | 17.77+0.9% | 20.42-17.8% | 20.18-5.0% | 18.05-7.6% | 17.62+15.8% | 24.85+21.5% | 21.25+12.2% |
| Long Term Debt | 0.00 | 0.00 | 4.11-33.4% | 0.00 | 0.00 | 0.00 | 6.17-17.3% | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | 2.11-18.5% | - | - | - | 2.59-3.4% | - |
| Other Liabilities | 2.67-44.5% | 3.43-37.6% | 0.00 | 4.09-40.1% | 4.81-31.0% | 5.50-20.6% | 0.00 | 6.83-14.4% |
| Total Liabilities | 23.43+2.5% | 21.20-8.3% | 26.64-20.7% | 24.27-13.6% | 22.86-13.8% | 23.12+4.4% | 33.61+9.8% | 28.08+4.3% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 381.26+17.7% | 415.56+89.1% | 384.36+58.1% | 406.92+48.5% | 324.00+7.1% | 219.74-33.1% | 243.12+8.5% | 273.99+10.7% |
| Total Shareholders Equity | 381.26+17.7% | 415.56+89.1% | 384.36+58.1% | 406.92+48.5% | 324.00+7.1% | 219.74-33.1% | 243.12+8.5% | 273.99+10.7% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 381.26+17.7% | 415.56+89.1% | 384.36+58.1% | 406.92+48.5% | 324.00+7.1% | 219.74-33.1% | 243.12+8.5% | 273.99+10.7% |
| Total Liabilities & Stockholders Equity | 404.69+16.7% | 436.76+79.8% | 411.00+48.5% | 431.19+42.7% | 346.86+5.5% | 242.86-30.8% | 276.73+8.7% | 302.07+10.1% |
| Book Value Per Share per share | 3.68-2.1% | 4.02+30.1% | 3.90+14.0% | 4.18+7.7% | 3.76-15.9% | 3.09-36.6% | 3.42-16.2% | 3.88-14.5% |
| Tangible Book Value Per Share per share | 3.68-2.1% | 4.02+30.1% | 3.90+14.0% | 4.18+7.7% | 3.76-15.9% | 3.09-36.6% | 3.42-16.2% | 3.88-14.5% |
| Full-Time Employees people | 111-13.3% | - | 104-9.6% | 106-5.4% | 128+19.6% | - | 115+15.0% | 112 |
| Price to Book Ratio ratio | 2.31 | 3.25 | 1.96 | 3.19 | 3.28 | 1.63 | 2.08 | 2.29 |
| Return on Assets % | -37.35 | -39.79 | -37.65 | -36.90 | -40.62 | -44.76 | -48.12 | -41.59 |
| Return on Equity % | -39.80 | -42.57 | -41.27 | -39.73 | -43.82 | -48.45 | -54.73 | -45.98 |
| Return on Invested Capital % | -10.88 | -8.61 | -7.85 | -8.01 | -11.22 | -13.66 | -14.56 | -12.62 |
| Quick Ratio ratio | 13.19 | 16.33 | 14.13 | 14.65 | 16.13 | 12.00 | 10.56 | 13.15 |
| Current Ratio ratio | 13.19 | 16.33 | 14.13 | 14.65 | 16.13 | 12.00 | 10.56 | 13.15 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -41.49 | -35.77 | -30.50 | -32.59 | -36.35 | -30.02 | -36.31 | -34.57 |
| Depreciation | 0.26-16.1% | 0.27-10.0% | 0.32+6.7% | 0.29+7.4% | 0.31+14.8% | 0.30+15.4% | 0.30+15.4% | 0.27+3.8% |
| Other Funds (Non Cash) | 7.38+32.5% | 6.07+11.8% | 6.04+69.2% | 3.30+6.1% | 5.57+106.3% | 5.43+112.1% | 3.57+124.5% | 3.11+60.3% |
| Funds from Operations | -33.85 | -29.43 | -24.15 | -29.00 | -30.48 | -24.29 | -32.43 | -31.19 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 2.24 | -4.00 | 1.66-62.1% | 2.14-10.5% | -0.78-123.1% | -8.49 | 4.38+121.2% | 2.39-34.2% |
| Cash from Operating Activities | -31.61 | -33.43 | -22.48 | -26.85 | -31.26 | -32.77 | -28.05 | -28.80 |
| Capital Expenditures | -0.36 | -0.00 | -0.23 | -0.04 | -0.06 | -0.39 | -0.22 | -0.42 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 12.22 | -17.97-178.7% | 17.21-59.9% | -110.50-570.4% | -76.87-513.1% | 22.84 | 42.87+103.9% | 23.49 |
| Purchase of Investments | -47.78 | -77.97 | -45.29 | -165.50 | -124.37 | -64.66 | -34.63 | -54.01 |
| Sale Or Maturity of Investments | 60.00+26.3% | 60.00-31.4% | 62.50-19.4% | 55.00-29.0% | 47.50-29.6% | 87.50+65.9% | 77.50+55.0% | 77.50+45.6% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 11.86 | -17.98-180.1% | 16.98-60.2% | -110.53-579.1% | -76.93-520.8% | 22.45 | 42.66+103.5% | 23.07 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.83-99.4% | 62.13+24752.0% | 1.50+163.2% | 111.19+85430.8% | 134.72+16329.3% | 0.25-99.8% | 0.57-16.2% | 0.13+333.3% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.83-99.4% | 62.13+24752.0% | 1.50+163.2% | 111.19+85430.8% | 134.72+16329.3% | 0.25-99.8% | 0.57-16.2% | 0.13+333.3% |
| Proceedsfrom Stock Options | 0.68 | 60.88 | 245.68+43771.4% | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.56-13.8% | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.83-99.4% | 62.13+24752.0% | 1.50+163.2% | 111.19+85430.8% | 134.72+16329.3% | 0.25-99.8% | 0.57-16.2% | 0.13+333.3% |
| Net Change in Cash | -18.91-171.3% | 10.73 | -4.00-126.4% | -26.20 | 26.53 | -10.07-130.5% | 15.18 | -5.60 |
| Free Cash Flow | -31.96 | -33.43 | -22.71 | -26.89 | -31.32 | -33.16 | -28.27 | -29.21 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 15.73% | 10.7M | 68.2M | 1.58M |
| 2026-10-15 | 22.61% | 15.4M | 68.2M | 1.48M |
| 2026-09-30 | 23.92% | 16.3M | 68.2M | 1.51M |
| 2026-09-15 | 25.70% | 17.5M | 68.2M | 1.53M |
| 2026-08-31 | 25.33% | 17.3M | 68.2M | 1.67M |
| 2026-08-14 | 26.98% | 18.4M | 68.2M | 1.71M |
| 2026-07-31 | 34.71% | 21.8M | 62.8M | 1.67M |
| 2026-07-15 | 35.23% | 22.1M | 62.6M | 1.62M |
| 2026-06-30 | 35.32% | 22.1M | 62.6M | 1.95M |
| 2026-06-15 | 33.65% | 21.1M | 62.6M | 1.89M |
| 2026-05-29 | 35.78% | 21.9M | 61.3M | 1.83M |
| 2026-05-15 | 35.80% | 21.9M | 61.3M | 1.92M |
| 2026-04-30 | 36.60% | 22.0M | 60.1M | 1.88M |
| 2026-04-15 | 36.43% | 20.7M | 56.9M | 1.95M |
| 2026-03-31 | 33.98% | 19.3M | 56.9M | 1.66M |
| 2026-03-13 | 36.27% | 20.7M | 56.9M | 1.67M |
| 2026-02-27 | 38.28% | 21.8M | 56.9M | 1.58M |
| 2026-02-13 | 38.83% | 22.1M | 56.9M | 1.51M |
| 2026-01-30 | 39.96% | 21.6M | 54.2M | 1.49M |
| 2026-01-15 | 39.02% | 21.1M | 54.2M | 1.40M |
Option chain
Expiry 2026-11-20 · underlying 8.55, quoted 13 Nov 07:17 ET · ATM 9.00
Option quotes 12 Nov 15:03 ET. A date on a row is older than the last session (12 Nov). 44 rows.
Implied move 35.67% into expiry (call 2.450 + put 0.600 = 3.050 on 8.55)
Put/call open interest 0.14 (813 puts / 5,999 calls) · Put/call volume 4.55 (50 puts / 11 calls)
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call 1 Apr | 3.00 | ITM | 3.20 | 8.00 | 4.90 | 0.00 | 2227.8% +1816.6 | 5 | 0 | 0 | 0.979 | -0.017 | 0.001 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 411.0% 0.0 | 0 | 0 | 0 | -0.021 | -0.016 | 0.001 | |
| call 10 Nov | 4.00 | ITM | 2.20 | 7.00 | 4.90 | 0.00 | 1519.0% +1211.6 | 2 | 0 | 0 | 0.971 | -0.016 | 0.001 |
| put 26 Oct | OTM | 0.00 | 2.05 | 0.13 | 0.00 | 307.5% 0.0 | 22 | 0 | 0 | -0.029 | -0.016 | 0.001 | |
| call 26 Oct | 5.00 | ITM | 1.15 | 6.00 | 6.45 | 0.00 | 1167.1% +900.7 | 3 | 0 | 0 | 0.940 | -0.026 | 0.001 |
| put 27 Oct | OTM | 0.00 | 0.10 | 0.10 | 0.00 | 506.5% 0.0 | 54 | 0 | 0 | -0.135 | -0.087 | 0.003 | |
| call 24 Jun | 6.00 | ITM | 0.50 | 4.90 | 4.30 | 0.00 | 896.3% +660.3 | 1 | 0 | 0 | 0.882 | -0.038 | 0.002 |
| put 29 Oct | OTM | 0.00 | 2.45 | 0.20 | 0.00 | 236.1% 0.0 | 49 | 0 | 0 | -0.118 | -0.037 | 0.002 | |
| call 1 Jan | 7.00 | ITM | 0.00 | 4.90 | 0.00 | 0.00 | 988.8% +707.2 | 0 | 0 | 0 | 0.751 | -0.071 | 0.004 |
| put 28 Oct | OTM | 0.00 | 0.65 | 0.60 | 0.00 | 281.8% 0.0 | 76 | 0 | 0 | -0.249 | -0.071 | 0.004 | |
| call 1 Oct | 8.00 | ITM | 0.20 | 4.90 | 6.00 | 0.00 | 1061.4% +641.0 | 4 | 0 | 0 | 0.658 | -0.123 | 0.005 |
| put 30 Oct | OTM | 0.00 | 1.00 | 0.50 | 0.00 | 258.3% -162.1 | 98 | 0 | 0 | -0.342 | -0.122 | 0.005 | |
| call 6 Nov | 9.00 | ATM | 0.00 | 4.90 | 0.78 | 0.00 | 1119.7% +197.2 | 102 | 0 | 0 | 0.737 | -0.239 | 0.004 |
| put | ATM | 0.00 | 1.20 | 0.93 | 0.00 | 183.2% -739.9 | 209 | 50 | 25 | -0.263 | -0.239 | 0.004 | |
| call 9 Nov | 10.00 | OTM | 0.00 | 2.00 | 0.59 | 0.00 | 508.6% 0.0 | 906 | 0 | 0 | 0.562 | -0.160 | 0.005 |
| put 11 Nov | ITM | 0.10 | 4.90 | 2.52 | 0.00 | 807.2% +298.6 | 81 | 0 | 0 | -0.438 | -0.159 | 0.005 | |
| call 26 Oct | 11.00 | OTM | 0.00 | 4.90 | 1.00 | 0.00 | 554.3% 0.0 | 71 | 0 | 0 | 0.539 | -0.176 | 0.005 |
| put 22 Oct | ITM | 0.10 | 4.90 | 1.23 | 0.00 | 643.4% +83.4 | 35 | 0 | 0 | -0.461 | -0.176 | 0.005 | |
| call 9 Nov | 12.00 | OTM | 0.00 | 1.75 | 0.44 | 0.00 | 553.7% 0.0 | 1,082 | 0 | 0 | 0.493 | -0.176 | 0.005 |
| put 28 Oct | ITM | 1.15 | 5.90 | 3.61 | 0.00 | 687.1% +133.4 | 7 | 0 | 0 | -0.507 | -0.174 | 0.005 | |
| call 5 Nov | 13.00 | OTM | 0.00 | 4.90 | 0.10 | 0.00 | 583.8% 0.0 | 47 | 0 | 0 | 0.478 | -0.186 | 0.005 |
| put 2 Nov | ITM | 2.05 | 6.90 | 4.10 | 0.00 | 725.5% +133.4 | 164 | 0 | 0 | -0.522 | -0.186 | 0.005 | |
| call 28 Oct | 14.00 | OTM | 0.00 | 4.90 | 0.50 | 0.00 | 617.7% 0.0 | 3,273 | 0 | 0 | 0.466 | -0.196 | 0.005 |
| put 16 Oct | ITM | 3.00 | 7.80 | 3.85 | 0.00 | 739.2% +113.3 | 15 | 0 | 0 | -0.534 | -0.196 | 0.005 | |
| call 9 Nov | 15.00 | OTM | 0.00 | 4.90 | 0.05 | 0.00 | 648.0% 0.0 | 50 | 0 | 0 | 0.456 | -0.206 | 0.005 |
| put 1 Jan | ITM | 4.00 | 8.80 | 0.00 | 0.00 | 769.7% +113.5 | 0 | 0 | 0 | -0.543 | -0.205 | 0.005 | |
| call 21 Oct | 16.00 | OTM | 0.00 | 2.50 | 2.00 | 0.00 | 678.1% 0.0 | 15 | 0 | 0 | 0.448 | -0.214 | 0.005 |
| put 4 Nov | ITM | 5.00 | 9.80 | 6.80 | 0.00 | 797.3% +113.7 | 1 | 0 | 0 | -0.552 | -0.213 | 0.005 | |
| call 15 Oct | 17.00 | OTM | 0.00 | 4.90 | 1.00 | 0.00 | 703.1% 0.0 | 7 | 0 | 0 | 0.441 | -0.221 | 0.005 |
| put 1 Jan | ITM | 6.00 | 10.80 | 0.00 | 0.00 | 822.6% +114.0 | 0 | 0 | 0 | -0.559 | -0.221 | 0.005 | |
| call 2 Nov | 18.00 | OTM | 0.00 | 4.90 | 0.14 | 0.00 | 731.5% 0.0 | 251 | 0 | 0 | 0.435 | -0.229 | 0.005 |
| put 5 Nov | ITM | 7.00 | 11.80 | 9.05 | 0.00 | 845.9% +114.3 | 0 | 0 | 0 | -0.565 | -0.227 | 0.005 | |
| call 15 Jun | 19.00 | OTM | 0.00 | 4.90 | 1.65 | 0.00 | 744.8% 0.0 | 1 | 0 | 0 | 0.429 | -0.234 | 0.005 |
| put 1 Jan | ITM | 8.00 | 12.80 | 0.00 | 0.00 | 867.5% +114.6 | 0 | 0 | 0 | -0.570 | -0.233 | 0.005 | |
| call | 20.00 | OTM | 0.00 | 4.80 | 0.10 | -1.90 | 772.5% 0.0 | 67 | 11 | 11 | 0.425 | -0.241 | 0.005 |
| put 1 Jan | ITM | 9.00 | 13.80 | 0.00 | 0.00 | 887.5% +114.9 | 0 | 0 | 0 | -0.575 | -0.239 | 0.005 | |
| call 1 Jan | 21.00 | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 782.4% 0.0 | 0 | 0 | 0 | 0.419 | -0.245 | 0.005 |
| put 5 Aug | ITM | 10.00 | 14.90 | 9.80 | 0.00 | 926.7% +135.3 | 1 | 0 | 0 | -0.579 | -0.244 | 0.005 | |
| call 26 Oct | 22.00 | OTM | 0.00 | 4.90 | 0.15 | 0.00 | 799.7% 0.0 | 106 | 0 | 0 | 0.415 | -0.250 | 0.005 |
| put 1 Jan | ITM | 11.00 | 15.90 | 0.00 | 0.00 | 943.8% +135.6 | 0 | 0 | 0 | -0.583 | -0.248 | 0.005 | |
| call 5 Aug | 23.00 | OTM | 0.00 | 4.90 | 2.00 | 0.00 | 816.0% 0.0 | 1 | 0 | 0 | 0.412 | -0.254 | 0.005 |
| put 5 Aug | ITM | 12.00 | 16.90 | 11.10 | 0.00 | 960.4% +135.9 | 1 | 0 | 0 | -0.587 | -0.253 | 0.005 | |
| call 5 Aug | 24.00 | OTM | 0.00 | 4.90 | 1.75 | 0.00 | 831.4% 0.0 | 1 | 0 | 0 | 0.409 | -0.259 | 0.005 |
| put 1 Jan | ITM | 13.00 | 17.90 | 0.00 | 0.00 | 976.1% +136.2 | 0 | 0 | 0 | -0.590 | -0.257 | 0.005 | |
| call 1 Oct | 25.00 | OTM | 0.00 | 2.25 | 2.52 | 0.00 | 854.4% 0.0 | 4 | 0 | 0 | 0.407 | -0.264 | 0.005 |
| put 1 Jan | ITM | 14.00 | 18.60 | 0.00 | 0.00 | 930.6% +76.0 | 0 | 0 | 0 | -0.593 | -0.261 | 0.005 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-23 | 8-K | Current report | 2026-10-23 | SEC |
| 2026-10-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-20 | SEC |
| 2026-10-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-10-01 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-10-01 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-28 | SEC |
| 2026-09-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-24 | SEC |
| 2026-08-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-26 | SEC |
| 2026-08-26 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-03 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-03 | 8-K | Current report | 2026-08-03 | SEC |
| 2026-07-30 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-07-30 | 8-K | Current report | 2026-07-28 | SEC |
| 2026-07-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-24 | SEC |
| 2026-07-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-06 | SEC |
| 2026-07-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-22 | 8-K | Current report | 2026-06-18 | SEC |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-15 | SCHEDULE 13G | SEC | ||
| 2026-05-12 | SCHEDULE 13G/A | SEC | ||
| 2026-05-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-04 | 8-K | Current report | 2026-05-04 | SEC |
| 2026-04-28 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-04-28 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-04-28 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-18 | SEC |
| 2026-03-31 | 8-K | Current report | 2026-03-31 | SEC |
| 2026-02-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-02-24 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 275.92K | 3 |
| 2026-09 | 0 | 0 | 189.36K | 2 |
| 2026-08 | 0 | 0 | 1.05M | 1 |
| 2026-07 | 0 | 0 | 161.06K | 3 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 702.69K | 1 |
| 2026-01 | 0 | 0 | 80.43K | 2 |
| 2025-12 | 0 | 0 | 496.62K | 3 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Nextech Invest Ltd. | 6.92% |
| BlackRock, Inc. | 6.59% |
| EcoR1 Capital, LLC | 6.50% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.39% |
| VIKING GLOBAL INVESTORS LP | 4.95% |
| SR ONE CAPITAL MANAGEMENT, LP | 4.46% |
| Venrock Adviser, LLC | 4.17% |
| STATE STREET CORP | 3.98% |
| NEA Management Company, LLC | 3.98% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.82% |
Funds
| Fund | % owned |
|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3.15% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.82% |
| iShares Russell 2000 ETF | 1.88% |
| ACAP Strategic Fund | 1.79% |
| T. Rowe Price Health Sciences Fund, Inc. | 1.48% |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1.22% |
| T. Rowe Price New Horizons Fund, Inc. | 1.08% |
| Eventide Healthcare & Life Sciences Fund | 0.92% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.91% |
| Fidelity Small Cap Index Fund | 0.79% |
OakChart. ORIC. Cached 15 minutes. Terms